Reach Us +1-217-403-9671
Glipizide Pharmacokinetics In Healthy And Diabetic Volunteers | 8233
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Glipizide pharmacokinetics in healthy and diabetic volunteers

2nd World Congress on Bioavailability & Bioequivalence: Pharmaceutical R & D Summit-2011 and International Conference on Pharmaceutics & Novel Drug Delivery Systems

Muhammad Atif, Syed Azhar Syed Sulaiman, Asrul Akmal Shafi e

ScientificTracks Abstracts: JBB

DOI: 10.4172/2153-2435.10000S4

Purpose: Disease state may contribute to alteration on drug pharmacokinetics. Th e purpose of this study was to determine the eff ect of non-insulin dependent diabetes mellitus (NIDDM) on the pharmacokinetics of glipizide. Method: An open, single-dose, parallel design was applied to the study. Glipizide tablet (5 mg) was administered to healthy and diabetic human volunteers aft er over- night fast. Blood samples were collected, centrifuged and the plasma assayed using a sensitive and validated reverse phase high performance liquid chromatography (RP- HPLC) method. Various pharmacokinetic parameters were computed from the data obtained. Results: Th e AUC 0-∞ values for healthy and diabetic volunteers was 1878?195 and 1723?138 ng.h/ml respectively; these values were not signifi cantly diff erent (p > 0.05). Th e t 1/2 for healthy volunteers was 3.04?0.27 h while that for diabetic subjects was 2.98?0.16 h. Clearance for healthy and diabetic volunteers was 0.59?0.06 and 0.64?0.05 ml/min/kg, respectively. All the foregoing and other pharmacokinetic parameters assessed not signifi cantly diff erent when compared for healthy and diabetic volunteers (p > 0.05). Conclusion: Although glipizide showed slightly more rapid clearance from the body of diabetic volunteers than from healthy volunteers, this diff erence, like those for other pharmacokinetic parameters, was not signifi cant (p > 0.05).